BRPI0918846A2 - inibidores de cinase heterocíclica - Google Patents
inibidores de cinase heterocíclicaInfo
- Publication number
- BRPI0918846A2 BRPI0918846A2 BRPI0918846A BRPI0918846A BRPI0918846A2 BR PI0918846 A2 BRPI0918846 A2 BR PI0918846A2 BR PI0918846 A BRPI0918846 A BR PI0918846A BR PI0918846 A BRPI0918846 A BR PI0918846A BR PI0918846 A2 BRPI0918846 A2 BR PI0918846A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- heterocyclic kinase
- heterocyclic
- inhibitors
- kinase
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9366408P | 2008-09-02 | 2008-09-02 | |
| PCT/EP2009/061188 WO2010026122A1 (en) | 2008-09-02 | 2009-08-31 | Heterocyclic pim-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0918846A2 true BRPI0918846A2 (pt) | 2019-09-24 |
Family
ID=41170173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918846A BRPI0918846A2 (pt) | 2008-09-02 | 2009-08-31 | inibidores de cinase heterocíclica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8759338B2 (enExample) |
| EP (1) | EP2344473B1 (enExample) |
| JP (1) | JP5584215B2 (enExample) |
| KR (1) | KR20110056399A (enExample) |
| CN (1) | CN102197032B (enExample) |
| AU (1) | AU2009289317A1 (enExample) |
| BR (1) | BRPI0918846A2 (enExample) |
| CA (1) | CA2735782A1 (enExample) |
| EA (1) | EA201100427A1 (enExample) |
| MX (1) | MX2011002362A (enExample) |
| WO (1) | WO2010026122A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| DK2734205T3 (en) | 2011-07-21 | 2018-06-14 | Tolero Pharmaceuticals Inc | Heterocyclic Protein Kinase Inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| TWI662030B (zh) | 2013-01-15 | 2019-06-11 | 英塞特控股公司 | 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CN108373476B (zh) * | 2017-01-13 | 2021-06-01 | 成都地奥制药集团有限公司 | 一种激酶抑制剂及其制备和应用 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| MX2020010556A (es) | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
| CN109369513B (zh) * | 2018-11-20 | 2020-08-25 | 都创(上海)医药科技有限公司 | 一种fbdd常用分子片段的制备方法 |
| CN111362922A (zh) * | 2018-12-26 | 2020-07-03 | 上海喆邺生物科技有限公司 | 2,4-二氨基嘧啶衍生物及其用途 |
| HUE072069T2 (hu) | 2019-02-12 | 2025-10-28 | Sumitomo Pharma America Inc | 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| AU2023372386A1 (en) | 2022-10-31 | 2025-05-08 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9312891D0 (en) * | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB0226724D0 (en) * | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004081000A1 (en) * | 2003-03-10 | 2004-09-23 | Astrazeneca Ab | Quinazoline derivatives |
| WO2004108707A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyridazinil quinazoline derivatives for use in the treatment of tumours |
| US7223759B2 (en) | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
| US7390907B2 (en) * | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7781591B2 (en) | 2006-06-13 | 2010-08-24 | Wyeth Llc | Substituted 3-cyanopyridines as protein kinase inhibitors |
| JP2008501696A (ja) * | 2004-06-04 | 2008-01-24 | アンフォラ ディスカバリー コーポレーション | Ａｔｐ利用酵素阻害活性を示すキノリンおよびイソキノリン系化合物、ならびにその組成物および使用 |
| WO2007027729A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| MX2008015802A (es) * | 2006-06-13 | 2009-01-09 | Wyeth Corp | 3-cianopiridinas sustituidas como inhibidores de proteina quinasa. |
| DK2061765T3 (en) | 2006-09-01 | 2015-01-26 | Senhwa Biosciences Inc | Serine-threonine protein kinase AND PARP-MODULATOR |
| US8557830B2 (en) * | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
-
2009
- 2009-08-31 WO PCT/EP2009/061188 patent/WO2010026122A1/en not_active Ceased
- 2009-08-31 US US13/061,009 patent/US8759338B2/en not_active Expired - Fee Related
- 2009-08-31 JP JP2011524404A patent/JP5584215B2/ja not_active Expired - Fee Related
- 2009-08-31 AU AU2009289317A patent/AU2009289317A1/en not_active Abandoned
- 2009-08-31 EP EP09782379.3A patent/EP2344473B1/en not_active Not-in-force
- 2009-08-31 BR BRPI0918846A patent/BRPI0918846A2/pt not_active IP Right Cessation
- 2009-08-31 CN CN200980142961.3A patent/CN102197032B/zh not_active Expired - Fee Related
- 2009-08-31 MX MX2011002362A patent/MX2011002362A/es not_active Application Discontinuation
- 2009-08-31 KR KR1020117007561A patent/KR20110056399A/ko not_active Withdrawn
- 2009-08-31 EA EA201100427A patent/EA201100427A1/ru unknown
- 2009-08-31 CA CA2735782A patent/CA2735782A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8759338B2 (en) | 2014-06-24 |
| WO2010026122A1 (en) | 2010-03-11 |
| AU2009289317A1 (en) | 2010-03-11 |
| CN102197032B (zh) | 2014-07-23 |
| CA2735782A1 (en) | 2010-03-11 |
| EP2344473B1 (en) | 2014-04-16 |
| KR20110056399A (ko) | 2011-05-27 |
| JP5584215B2 (ja) | 2014-09-03 |
| MX2011002362A (es) | 2011-04-04 |
| US20110195956A1 (en) | 2011-08-11 |
| EP2344473A1 (en) | 2011-07-20 |
| CN102197032A (zh) | 2011-09-21 |
| JP2012501313A (ja) | 2012-01-19 |
| EA201100427A1 (ru) | 2011-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020024I1 (el) | Αναστολεiς βητα-λακταμασων | |
| CY2019027I2 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
| CY2019009I1 (el) | Αναστολεις πρωτεϊνικων κινασων | |
| BRPI0910668A2 (pt) | inibidores de proteína quinases | |
| BRPI0908494A2 (pt) | Inibidores de pirrolopirazina quinase | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
| EP2632898A4 (en) | HETEROCYCLIC TYROSINE KINASE HEMMER | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| EP2346508A4 (en) | HETEROCYCLIC KINASE HEMMER | |
| EP2192838A4 (en) | HETEROCYCLIC NEKROPTOSIS HEMMER | |
| EP2498607A4 (en) | Kinase Inhibitors | |
| EP2493313A4 (en) | Kinase Inhibitors | |
| BRPI0814797A2 (pt) | Inibidores dna-pk | |
| BRPI0922937A2 (pt) | inibidores de pirrolopirazinil uréia quinase | |
| ATE506358T1 (de) | 2-benzylpyridazinonderivate als met-kinasehemmer | |
| BRPI0922880A2 (pt) | compostos inibidores de quinase | |
| BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
| BRPI0920239A2 (pt) | compostos heterocíclicos como inibidores de proteínas quinases | |
| EP2558099A4 (en) | Kinase inhibitors | |
| BRPI0906705A2 (pt) | Composto heterocíclicos | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0912475A2 (pt) | compostos como inibidores de quinase | |
| BRPI0906838A2 (pt) | Pirimidinas como inibidores de quinase | |
| EP2222166A4 (en) | INHIBITORS OF HETEROCYCLIC KINASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |